Editorial
Cholangiocarcinoma: Challenges and future needs
Abstract
Cholangiocarcinoma (CCA) is a malignant neoplasm that
arises from the biliary tract epithelia. CCA is the second most
common primary liver tumour after hepatocellular carcinoma,
representing 10-25% of primary hepatic malignancies (1).
CCA is rare in many parts of the world, such as Europe and
the United States (US), accounting for <3% of all malignant
tumours. However, there is a dramatic geographic variation in its
incidence, which reflects regional differences in risk factors and
epidemiology (2,3).
arises from the biliary tract epithelia. CCA is the second most
common primary liver tumour after hepatocellular carcinoma,
representing 10-25% of primary hepatic malignancies (1).
CCA is rare in many parts of the world, such as Europe and
the United States (US), accounting for <3% of all malignant
tumours. However, there is a dramatic geographic variation in its
incidence, which reflects regional differences in risk factors and
epidemiology (2,3).
